TY - JOUR
T1 - Recurrent epithelial ovarian cancer
T2 - An update on treatment
AU - Foley, Olivia W.
AU - Rauh-Hain, J. Alejandro
AU - del Carmen, Marcela G.
PY - 2013/4/26
Y1 - 2013/4/26
N2 - An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
AB - An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=84876207877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876207877&partnerID=8YFLogxK
M3 - Review article
C2 - 23781692
AN - SCOPUS:84876207877
SN - 0890-9091
VL - 27
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 4
ER -